EUVIMEDPoznaj EUVIMED
Multizentrische StudieBeobachtungsstudie

Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study

Akinori Sairaku iD, Michitaka Amioka, Yoshikazu Watanabe, Shunsuke Tomomori iD, Yukihiro Fukuda, Yukiko Nakano

Pacing and Clinical Electrophysiology · 2026

DOI: 10.1111/pace.70301 ↗

At a glance

Multizentrische Studie in Pacing and Clinical Electrophysiology, 2026. Written by Akinori Sairaku and 5 co-authors. Institution: Department of Cardiology, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan. Major MEDLINE topics: Anti-Arrhythmia Agents, Atrial Flutter, Magnesium Sulfate, Pyrimidinones. 13 references.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Background

Pharmacologic cardioversion of atrial flutter (AFL) remains challenging, particularly in older or frail patients who are not candidates for catheter ablation. Nifekalant is effective for AFL but is limited by QT prolongation and the risk of torsades de pointes (TdP). Magnesium sulfate may mitigate this risk.

Methods

In this multicenter, investigator‐initiated pilot study, 86 patients with symptomatic persistent AFL received intravenous magnesium sulfate followed by nifekalant. The primary outcome was AFL termination within 60 min. Time to termination and safety outcomes, including TdP, were assessed. Multivariable logistic regression analyses were performed to identify factors associated with AFL termination.

Results

AFL terminated in 42 patients (48.8%). Among patients with successful cardioversion, 80% achieved termination within 20 min. Larger left atrial diameter was associated with a lower likelihood of AFL termination. Adverse events occurred in 2 patients (2.3%), including sinus pauses requiring pacemaker implantation and transient hypotension requiring vasopressor support. No cases of TdP were observed.

Conclusions

These findings suggest that the nifekalant–magnesium cocktail may be a feasible and potentially safe option for chemical cardioversion of AFL, warranting further investigation in larger studies.

Subjects

MeSH terms (MEDLINE)

Anti-Arrhythmia AgentsAtrial FlutterMagnesium SulfatePyrimidinonesAgedFemaleHumansMaleMiddle AgedPilot ProjectsTreatment Outcome

Author keywords

atrial flutterchemical cardioversionmagnesium sulfatenifekalanttorsades de pointes

Substances

Anti-Arrhythmia AgentsMagnesium SulfatenifekalantPyrimidinones

Authors and institutions

  • Department of Cardiology, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
  • Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
  • Department of Cardiology, Onomichi General Hospital, Onomichi, Japan.
  • Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Cardiology, Hiroshima Prefectural Hospital, Hiroshima, Japan.

ORCID profiles: Akinori Sairaku, Shunsuke Tomomori

Cite

APA

Sairaku, A., Amioka, M., Watanabe, Y., Tomomori, S., Fukuda, Y., & Nakano, Y. (2026). Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.70301

Vancouver

Sairaku A, Amioka M, Watanabe Y, Tomomori S, Fukuda Y, Nakano Y. Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study. Pacing and Clinical Electrophysiology. 2026. doi:10.1111/pace.70301

BibTeX
@article{Sairaku2026,
  author = {Sairaku, Akinori and Amioka, Michitaka and Watanabe, Yoshikazu and Tomomori, Shunsuke and Fukuda, Yukihiro and Nakano, Yukiko},
  title = {Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2026},
  doi = {10.1111/pace.70301}
}
Start for free →